Xiaowei Zhang1, Heng-Jie Cheng2, Peng Zhou2, Dalane W Kitzman2, Carlos M Ferrario3, Wei-Min Li4, Che Ping Cheng5. 1. Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Harbin, China. 2. Section on Cardiovascular Medicine, Wake Forest School of Medicine, Winston-Salem, NC, United States. 3. Department of Surgery, Wake Forest School of Medicine, Winston-Salem, NC, United States; Department of Internal Medicine-Nephrology, Wake Forest School of Medicine, Winston-Salem, NC, United States; Department of Physiology and Pharmacology, Wake Forest School of Medicine, Winston-Salem, NC, United States. 4. Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Harbin, China. Electronic address: liweimin_2009@163.com. 5. Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Harbin, China; Section on Cardiovascular Medicine, Wake Forest School of Medicine, Winston-Salem, NC, United States. Electronic address: ccheng@wakehealth.edu.
Abstract
BACKGROUND: Angiotensin-(1-7) [Ang-(1-7)] exhibits cardiovascular effects opposite those of angiotensin II (Ang II), thus providing protection against heart disease. However, how Ang-(1-7) imparts cardioprotection is unclear, and its direct cardiac effects are controversial. Whether heart failure (HF) alters cardiac contractile responses to Ang-(1-7) remains undetermined. We tested the hypothesis that in HF, Ang-(1-7) may produce positive modulation on [Ca2+]i regulation, enhancing left ventricular (LV) and myocyte contraction and relaxation via Ang-(1-7) Mas receptor coupled with nitric oxide (NO)/bradykinin (BK)-mediated mechanism. METHODS AND RESULTS: We measured LV contractility changes after Ang-(1-7) (650ng/kg, iv) and compared myocyte functional and [Ca2+]i transient ([Ca2+]iT) responses to Ang-(1-7) superfusion in 24 normal rats and 34 rats with isoproterenol-induced HF (3months after 170mg/kg, s.q. for 2days). To assess the mechanisms of altered HF responses to Ang-(1-7), subsets of HF myocytes were pretreated to inhibit NO synthase (L-NAME), BK (HOE-140), and Mas receptor (A-779) followed with Ang-(1-7). In normal rats, Ang-(1-7) produced no significant changes in LV and myocyte function. In HF rats, Ang-(1-7) significantly augmented LV contractility and relaxation with increased EES (51%), but decreased τ compared to baseline. Ang-(1-7) also significantly increased myocyte contraction (dL/dtmax, 30%), relaxation (dR/dtmax, 41%), and [Ca2+]iT. L-NAME increased, HOE-140 decreased, and A-779 prevented HF myocyte contractile responses to Ang-(1-7). CONCLUSIONS: In a rat model of HF, Ang-(1-7) increases [Ca2+]iT, and produces positive inotropic and lusitropic effects in the LV and myocytes. These effects are mediated by the Mas receptor and involve activation of NO/BK pathways.
BACKGROUND: Angiotensin-(1-7) [Ang-(1-7)] exhibits cardiovascular effects opposite those of angiotensin II (Ang II), thus providing protection against heart disease. However, how Ang-(1-7) imparts cardioprotection is unclear, and its direct cardiac effects are controversial. Whether heart failure (HF) alters cardiac contractile responses to Ang-(1-7) remains undetermined. We tested the hypothesis that in HF, Ang-(1-7) may produce positive modulation on [Ca2+]i regulation, enhancing left ventricular (LV) and myocyte contraction and relaxation via Ang-(1-7) Mas receptor coupled with nitric oxide (NO)/bradykinin (BK)-mediated mechanism. METHODS AND RESULTS: We measured LV contractility changes after Ang-(1-7) (650ng/kg, iv) and compared myocyte functional and [Ca2+]i transient ([Ca2+]iT) responses to Ang-(1-7) superfusion in 24 normal rats and 34 rats with isoproterenol-induced HF (3months after 170mg/kg, s.q. for 2days). To assess the mechanisms of altered HF responses to Ang-(1-7), subsets of HF myocytes were pretreated to inhibit NO synthase (L-NAME), BK (HOE-140), and Mas receptor (A-779) followed with Ang-(1-7). In normal rats, Ang-(1-7) produced no significant changes in LV and myocyte function. In HF rats, Ang-(1-7) significantly augmented LV contractility and relaxation with increased EES (51%), but decreased τ compared to baseline. Ang-(1-7) also significantly increased myocyte contraction (dL/dtmax, 30%), relaxation (dR/dtmax, 41%), and [Ca2+]iT. L-NAME increased, HOE-140 decreased, and A-779 prevented HF myocyte contractile responses to Ang-(1-7). CONCLUSIONS: In a rat model of HF, Ang-(1-7) increases [Ca2+]iT, and produces positive inotropic and lusitropic effects in the LV and myocytes. These effects are mediated by the Mas receptor and involve activation of NO/BK pathways.
Authors: Michikado Iwata; Randy T Cowling; Devorah Gurantz; Cristina Moore; Shen Zhang; Jason X-J Yuan; Barry H Greenberg Journal: Am J Physiol Heart Circ Physiol Date: 2005-07-15 Impact factor: 4.733
Authors: Annemarieke E Loot; Anton J M Roks; Robert H Henning; René A Tio; Albert J H Suurmeijer; Frans Boomsma; Wiek H van Gilst Journal: Circulation Date: 2002-04-02 Impact factor: 29.690
Authors: D Grimm; D Elsner; H Schunkert; M Pfeifer; D Griese; G Bruckschlegel; F Muders; G A Riegger; E P Kromer Journal: Cardiovasc Res Date: 1998-01 Impact factor: 10.787
Authors: Itamar Couto Guedes Jesus; Thássio Ricardo Ribeiro Mesquita; André Luís Lima Monteiro; Amanda Borges Parreira; Anderson Kenedy Santos; Elizeu Lucas Xavier Coelho; Mário Morais Silva; Lucas A C Souza; Maria José Campagnole-Santos; Robson Souza Santos; Silvia Guatimosim Journal: Am J Physiol Cell Physiol Date: 2020-01-08 Impact factor: 4.249
Authors: Santiago Reyes; Che Ping Cheng; Drew J Roberts; Tomohisa Yamashita; Sarfaraz Ahmad; Jessica L VonCannon; Kendra N Wright; Louis J Dell'Italia; Jasmina Varagic; Carlos M Ferrario Journal: Int J Cardiol Date: 2019-10-08 Impact factor: 4.164